

The Swedish National March Cohort

<https://neurodegenerationresearch.eu/survey/the-swedish-national-march-cohort/>

Title of cohort

The Swedish National March Cohort

Acronym for cohort

SNMC

Name of Principal Investigator - Title

Prof

Name of Principal Investigator - First name

Weimin

Name of Principal Investigator - Last name

Ye

Address of institution -Institution

Department of Medical Epidemiology and Biostatistics

Address of institution - Street address

Nobels Väg 12A

Address of institution - City

Stockholm

Address of institution - Postcode

17177

Country

Sweden

Website

<http://ki.se/en/meb/the-swedish-national-march-cohort-nmc>

Contact email

weimin.ye@ki.se

Funding source

Cancerfonden

Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?

Neurodegenerative disease in general

Q1b. When are studies on the above condition(s) expected to become possible?

2016-2020

Q2a. In a single sentence what is the stated aim of the cohort?

The purpose of the SNMC is to create a large prospective cohort to investigate associations between lifestyle factors and chronic diseases.

Q2b. What distinguishes this cohort from other population cohorts?

Very detailed information on physical activity and lifestyle factors, with low percentages of missingness

Q3a. i) Number of publications that involve use of your cohort to date

13

Q3a.ii) Please give up to three examples of studies to date (Principal Investigator, Institution, Title of Study)

Bellocco. Karolinska Institutet. Effects of physical activity, body mass index, waist-to-hip ratio and waist circumference on total mortality risk in the Swedish National March Cohort. | Andersen. Karolinska Institutet. Dose-response relationship of total and leisure time physical activity to risk of heart failure: a prospective cohort study. | Bellocco. Karolinska Institutet. A prospective cohort study of the combined effects of physical activity and anthropometric measures on the risk of postmenopausal breast cancer

Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available

<http://ki.se/en/meb/the-swedish-national-march-cohort-nmc>

Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the population

Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:

Q4a. Study criteria: what is the age range of participants at recruitment? To:

94

Q4b. Study criteria: what are the inclusion criteria?

Voluntary enrollment

Q4c. Study criteria: what are the exclusion criteria?

Incorrect national registration number

Q5. What is the size of the cohort (i.e. how many participants have enrolled)?

More than 15,000 participants

Q6a. Please describe what measures are used to characterise participants

Antropometric measures, lifestyle factors, medical history.

Q6b. Are there additional measures for participants with a clinical disorder?

No

Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?

No

If yes please specify

Q7. What is the study design (select all that apply)?

Prospective cohort| Cross sectional survey

Q8. Are your cases matched by

None

Q9a. Does your study include a specialised subset of control participants?

Q9b. If your study includes a specialised subset of control participants please describe

Q10a. i) Please enter the data collection start date

01/09/1997

Q10a. ii) Please enter the data collection end date

01/09/1997

Q10a. iii) Is data collection for this study

At the planning stage| Data collection ongoing| Data analysis ongoing

Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?

Yes - intend to apply for funding

Q11. Is data collected

Through links to medical records

Other please specify here

Questionnaire at baseline, follow-up through linkages to National Registers

Q12. Is there a system in place to enable re-contact with patients to ask about participation in future studies?

Yes (participants given permission to be re-contacted via PIs)

Q13a. Please give information on the format and availability of data stored in a database (1)

Data summarised in database

% available

100

Q13a. Please give information on the format and availability of data stored in a database (2)

No

% available

Q13a. Please give information on the format and availability of data stored in a database (3)

Database on spreadsheet (e.g. excel)

% available

100

Q13a. Please give information on the format and availability of data stored in a database (4)

No

% available

Other (please specify)

% available

Q13b. Please give information on the format and availability of data held as individual records (1)

Data is held as individual records

% available

100

Q13b. Please give information on the format and availability of data held as individual records (2)

No

% available

Q13b. Please give information on the format and availability of data held as individual records (3)

Data held on computer based records

% available

100

Q13b. Please give information on the format and availability of data held as individual records (4)

Data held on cards

% available

100

Please specify language used

English

Q14a. Is data available to other groups?

Yes

Q14b. If data is available to other groups what is the access policy/mechanisms for access?

Apply to PI or co-ordinator at resource| Access through collaboration with PI only| Access committee mechanism| Local/ regional access| National access| International access| Resource has own ethics approval so usually no need for separate external ethics approval

Q15. What data sharing policy is specified as a condition of use?

No policy exists

Q16a. Are tissues/samples/DNA available to other groups?

No

Q16b i) If yes, please describe below:

Q16b. ii) In what form are tissues/samples/DNA supplied?

Q16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?

Q17. Is information on biological characteristics available to other groups?

Number of Patients

% of total cohort

Types:

Population Cohorts

Member States:

Sweden

Diseases:

Neurodegenerative disease in general

Years:

2016

Database Categories:

N/A

Database Tags:

N/A